Free tool
FAERS Monitor: Zaltrap
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125418 or its brand name (Zaltrap, Ziv-Aflibercept). Reports on generic versions are filed under their own applications.
Reports
1,304
Serious
1,220
94% of reports
Hospitalization
592
Death reported
207
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea178
- hypertension137
- neutropenia105
- asthenia73
- vomiting68
- proteinuria64
- death61
- nausea59
- disease progression49
- fatigue48
- stomatitis43
- abdominal pain42
- pyrexia42
- febrile neutropenia40
- decreased appetite39
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 20 |
| 2013 | 120 |
| 2014 | 114 |
| 2015 | 105 |
| 2016 | 109 |
| 2017 | 115 |
| 2018 | 258 |
| 2019 | 184 |
| 2020 | 92 |
| 2021 | 28 |
| 2022 | 21 |
| 2023 | 41 |
| 2024 | 64 |
| 2025 | 19 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,855 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| proteinuriaSignal | 64 | 54.5 | 42.9 | 3,298 |
| neutropeniaSignal | 105 | 12.5 | 10.4 | 1,102 |
| stomatitisSignal | 43 | 11.4 | 8.5 | 400 |
| hypertensionSignal | 137 | 10.4 | 8.9 | 1,171 |
| febrile neutropeniaSignal | 40 | 9.7 | 7.2 | 305 |
| disease progressionSignal | 49 | 6.7 | 5.1 | 232 |
| diarrhoeaSignal | 178 | 4.4 | 3.9 | 487 |
| astheniaSignal | 73 | 3.1 | 2.5 | 106 |
| abdominal painSignal | 42 | 2.9 | 2.2 | 51 |
| decreased appetiteSignal | 39 | 2.7 | 2.0 | 41 |
| vomitingSignal | 68 | 2.3 | 1.9 | 52 |
| pyrexia | 42 | 2.0 | 1.5 | 19 |
| nausea | 59 | 1.2 | 0.9 | 2 |
| death | 61 | 1.1 | 0.9 | 1 |
| fatigue | 48 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.